期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 116, 期 1, 页码 63-74出版社
WILEY
DOI: 10.1002/jso.24627
关键词
adoptive cell therapy; CAR T cells; chimeric antigen receptor; checkpoint blockade; immunotherapy
资金
- Memorial Sloan-Kettering Cancer Center [SU2C-AACR-DT1012]
- National Cancer Institute [P30-CA008748]
- Congressionally Directed Medical Research Programs [BC132124, LC110202, PR101053]
- CDMRP [PR101053, 547075, LC110202, 545913, BC132124, 672101] Funding Source: Federal RePORTER
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据